Publication | Open Access

217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)

Patient-reported OutcomesBreast OncologyMedicineCancer ManagementClinical TrialsBreast CancerCancer TreatmentOncologyRadiation OncologyHealth Sciences